Relationships between Heterotopic Ossification Volume and Functional and Quality of Life Endpoints in Fibrodysplasia Ossificans Progressiva

Elisabeth J.M. Verburg-Baltussen¹, Niels Dunnewind¹, Sonja Kroep¹, Ben van Hout¹, Elaine A. Böing², Richard Keen³

¹OPEN Health, Rotterdam, Netherlands; ²Ipsen, Cambridge, MA, USA; ³Royal National Orthopaedic Hospital, Stanmore, UK. Presenting author: Elaine A. Böing (elaine.boing@ipsen.com)

Background

- Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, genetic disorder of heterotopic ossification (HO) resulting in loss of joint function, progressive restriction of movement, and severe disability.¹
- New HO volume has been accepted by regulators as a primary endpoint for trials in FOP.²
 However, its relationship with outcomes which are likely relevant in health technology
 assessments, such as joint function and quality of life (QoL), warrants additional
 exploration.

Objective

To examine the relationships between HO volume and functional and QoL endpoints in patients with FOP.

Methods

- Data from 171 patients from the MOVE trial and the FOP Natural History Study (NHS) were pooled for this analysis:
- MOVE (NCT033126343) was a phase 3, multicenter, open-label trial of patients with FOP who received oral palovarotene.
- The FOP NHS was an international, observational, non-interventional study of patients with FOP followed for 36 months.
- Relationships were examined between HO volume and functional and QoL outcomes
 (including annualized change in these outcomes; Table 1). Additionally, the extent to which
 HO in individual body regions affected functional and QoL outcomes was evaluated.
- The Cumulative Analogue Joint Involvement Scale (CAJIS) assesses total body and regional mobility burden of FOP in 15 anatomic locations.
- The FOP Physical Function Questionnaire (FOP-PFQ) is a disease-specific instrument that includes questions related to activities of daily living and physical functioning.
- The Patient Reported Outcome Measure Information System (PROMIS) is a generic patient-reported outcome measure of physical and mental function.
- Spearman correlation coefficients were computed between the variables of interest at baseline and year 1 (annualized change).
- Various mixed effect regression models were fitted, including a patient-level random effect model, to account for correlations among repeated measures on the same patient. Model types aligning with the data characteristics of the outcome variables were used.
- First, best model fit was assessed per Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) using multiple predictor sets (selection per BIC is presented in this poster). For each outcome, two main predictor sets were compared:
 - HO volume in individual body regions (i.e., chest, arms, torso, hips and legs);
 - HO volume in upper and lower extremities.
- Second, the regression coefficients of the models were examined in terms of magnitude, direction, and statistical significance to determine whether positive or negative relationships could be confirmed.

Results

- Figure 1 presents the Spearman correlation coefficients. Compared with baseline, relationships at year 1 (annualized changes) were less pronounced.
- Table 2 presents the results from converged mixed regression models:

Table 1. Description of the data included in the analysis

- As expected, regression coefficients generally confirmed positive relationships between HO volume and CAJIS/FOP-PFQ, and negative relationships between HO volume and PROMIS.
- Statistically significant relationships (p<0.05) were found between HO volume in certain body regions and endpoint scores (e.g.,
 HO volume in upper extremities and observed/annualized change in CAJIS scores, and FOP-FPQ observed scores).
- HO volume in the upper or lower extremities was significantly associated with change in upper extremity CAJIS scores, observed FOP-PFQ scores, and changes in FOP-PFQ scores (p<0.05).

Measure Unit				Number of regions/questions			Conversion						Variables used in analysis						
HO volume mm ³				9			Normalized per region to a mean of 0 and a standard deviation of 1, pooling all timepoints						 Total HO volume HO volume by body region HO volume by upper and lower extremity 						
CAJIS	5	Score of	0,1, or 2	!	15				NA					CAJIS total scoreCAJIS upper and lower extremity score					
FOP-PFQ	5-	point Lil	cert scal	е	28			Percentage of the worst possible score (PWPS)					•						
PROMIS	20)- or 5-po sca		rt		10	Summary scores were converted into T-score mean of 50 and a standard deviation of 10							DD 01410 14					
Figure	1. Sp	earm	an co	rrelat	ion co	effici	ents a	a) at b	aselin	e and b) in ye	ear 1	(annı	ualize	d cha	nge)				
a)	Total HO	HO upper extr.	HO lower extr.	HO torso	HO chest	HO arms	HO hips	HO legs		b)	Total HO	HO upper extr.	HO lower extr.	HO torso	HO chest	HO arms	HO hips	HO legs	
CAJIS total score	0.73*	0.69*	0.67	0.38	0.60	0.66	0.69	0.61	- 0.8	CAJIS total score	0.24	0.23	0.19	0.17	0.22	0.11	0.15	0.10	
CAJIS per extr. score	0.56	0.65	0.51	0.36	0.54	0.66	0.48	0.36	- 0.6	CAJIS upper extr. score	0.14	0.17	0.07	0.05	0.11	0.18	0.08	0.05	-
CAJIS wer extr. score	0.67	0.52	0.62	0.23	0.42	0.53	0.73	0.72	- 0.4	CAJIS lower extr. score	0.22	0.13	0.26	0.23	0.11	0.05	0.18	0.13	-
	*	0.65	0.60	0.19	0.48	0.64	0.60	0.65	- 0.2	FOP-PFQ PWPS total score	0.48	0.25	0.47	0.33	0.26	0.06	0.43	0.13	-
FOP-PFQ PWPS total score	0.67	0.00																	
total score FOP-PFQ PWPS	0.67	0.70	0.54	0.24	0.54	0.65	0.46	0.53	- 0.2	FOP-PFQ PWPS upper extr. score	0.28	0.09	0.41	0.27	0.14	0.00	0.30	0.17	
FOP-PFQ PWPS per extr. score	*	*	*									0.09		0.27	0.14	0.00			
FOP-PFQ PWPS total score FOP-PFQ PWPS per extr. score FOP-PFQ PWPS wer extr. score PROMIS Physical Health	0.62	0.70	0.54	0.24	0.54	0.65	0.46	0.53	0.2	upper extr. score FOP-PFQ PWPS	0.28	*	0.41	0.27	*		0.30	0.17	

CONCLUSIONS

- The Spearman correlation coefficients, as well as results from the mixed regression models, confirm logical, significant relationships between HO volume and CAJIS and FOP-PFQ.
- There are insufficient data to confirm or reject a relationship between HO volume and PROMIS.
- These results help to better understand the associations between HO volume and functional and QoL endpoints in FOP.

Table 2. Direction and significance of relationships between HO volume in body regions and functional and QoL endpoints

	CAJIS Total			-PFQ otal	PROM	IIS PH	PROMIS MH		
Body region/extremity with HO volume	OS	ACS	OS	ACS	OS*	ACS*	OS*	ACS	
Chest									
Arms						0			
Torso						0			
Hips					0	0	0		
Legs						0			
Upper extremities									
Lower extremities		0				0	0		
	CVIIC	Unner	CALIC	Lower	EOD	-PFO	FOP-PFO		

	CAJIS Extre	Upper mities		Lower mities		-PFQ per	FOP-PFQ Lower		
					Extre	mities	Extremities		
Body region/extremity with HO volume	OS	ACS	OS	ACS	OS	ACS*	OS	ACS	
Chest									
Arms		0				0			
Torso									
Hips				0					
Legs									
Upper extremities									
Lower extremities									
 Positive statistically significant No statistically significant relati Negative statistically significant 	onship		HO volu	red model p ime in individ ime in uppel	dual body r	egions <u>or</u>			

Abbreviations ACS: annualized change score; AIC: Akaike information criterion; BIC: Bayesian information criteria; Extr.: extremities; CAJIS: Cumulative Analogue Joint Involvement Scale; FOP-PFQ: FOP Physical Function Questionnaire; HO: heterotopic ossification; MH: mental health; NA: not applicable; OS: observed score; PH: physical health; PROMIS: Patient-Reported Outcomes Measurement Information System; PWPS: percentage of the worst possible score.

Abbreviations: ACS: annualized change score; BIC: Bayesian information criteria; MH: mental health; OS: observed score; PH: physical health.

*No significant model available for comparison

References 1. Kaplan FS et al. Best Pract Res Clin Rheumatol. 2008;22(1):191–205; **2.** Hsiao EC et al. Br J Clin Pharmacol. 2019;85(6): 1199–1207; **3.** ClinicalTrials.gov. An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (MOVE); **4.** ClinicalTrials.gov. A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP).

Author Contributions Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: **EVB, ND, SK, BH, EAB**; Drafting of the publication, or revising it critically for important intellectual content: **EVB, ND, EAB, RK**; Final approval of the publication: **EVB, ND, SK, BH, EAB, RK**.

Disclosures EVB, ND, SK, BH: Employees of OPEN Health; **EAB**: Employee and shareholder of Ipsen; **RK**: Research Investigator: Clementia/Ipsen, Kyowa Kirin, Regeneron; Advisory board: IFOPA FOP Registry Medical Advisory Board, International Clinical Council on FOP.

Medical Writing Support The authors thank Carla Kraan and Ana Moura of OPEN Health for design support, which was sponsored by Ipsen in accordance with Good Publication Practice guidelines.

